<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733421</url>
  </required_header>
  <id_info>
    <org_study_id>2008HV001</org_study_id>
    <secondary_id>EudraCT number 2008-000791-24</secondary_id>
    <nct_id>NCT00733421</nct_id>
  </id_info>
  <brief_title>The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery</brief_title>
  <official_title>The Effect of Anti-inflammatory Analgesics on Bone Repair, Pain and Gastro-intestinal Side Effects After Hallux Valgus Surgery; a Prospective Randomised Double-blind Placebo Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of none-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase
      inhibitors (Coxibs) on the formation of bone and fracture healing have been a matter of
      debate since long.

      There is, however, limited data in humans and further prospective randomised studies are
      warranted. Ekman et al studied in a prospective randomised double blind study the effects of
      celecoxib, a selective cox-II-inhibitor, on pain and bone healing following spine surgery.
      They found significant effects on reduction of pain and need for opioid analgesics
      postoperatively but could see no negative effects the numbers of &quot;none-unions&quot; at a 1-year
      follow up 3.

      In a similar prospective randomised double-blind study design significant effects in
      reduction of pain and need for rescue analgesia was seen from the use of celecoxib in the
      perioperative multi-modal pain strategy for cruciate-ligament reconstruction and no negative
      effects could bee seen on six month follow-up of the strength of the reconstructed ligament.

      The aim of the present study is to further study the effects of the perioperative use of
      etoricoxib, a selective cox-II-inhibitor (Coxibs), in a prospective randomised double-blind
      study on bone healing, pain and need for rescue analgesia in patients undergoing elective
      Hallux Valgus surgery with a standardised surgical technique including an osteotomy of
      metatarsale I and excision of exostosis.

      Study population 100 American Society of Anesthesiology (ASA) physiological status1-2
      patients scheduled for elective hallux valgus (HV) surgery

      The patients are going to be randomised into 2 groups, 50 patients in each;

        1. etoricoxib 90 mg once daily x 5

        2. tramadol 100 mg twice daily x 5

      First line rescue medication t. paracetamol 1 gr up to 4 gram daily Second line rescue t.
      oxycodone 10 mg

      Primary study variables:

        -  X-ray evaluation (computer tomography (CT)-investigation) of bone healing assessed a
           CT-scan modelling of the osteotomy at twelve weeks after surgery

        -  Number of patients requiring rescue medication

        -  Patient assessment using &quot;brief pain inventory&quot; 24 hours and 2 weeks after surgery

      Secondary study variables are;

        -  Visual Analogue Scale (VAS) grading Day 1-7

        -  Compliance to base medication

        -  Need for rescue analgesia Day 1-7

        -  Adverse Effects

             -  Experience of any emetic symptoms

             -  Experience of any gastrointestinal symptoms

        -  Satisfaction with pain medication Day 20

        -  Wound dressing Day 20

        -  Clinical evaluation 17 weeks, final assessment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Requiring Rescue Medication</measure>
    <time_frame>7 day study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain</measure>
    <time_frame>The first 7 days after surgery, during study pain medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to Base Medication</measure>
    <time_frame>7-day study period, during study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal Symptoms</measure>
    <time_frame>during the 7- day pain medication period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizziness/Sleepiness</measure>
    <time_frame>During the 7-day pain medication period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Healing</measure>
    <time_frame>16 week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Pain Medication</measure>
    <time_frame>during the first 20 days after surgery, 1st outpatient clinic visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessed Overall Satisfaction With Surgery/Outcome</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessed Quality of Life</measure>
    <time_frame>At 16-week post surgery follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active study drug:
Etoricoxib 90 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tramadol 100 mg slow release twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoricoxib</intervention_name>
    <description>90 mg once daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Arcoxia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tramadol</intervention_name>
    <description>100 mg twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Tiparol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health ASA 1-2 patients 18-65 years of age

        Exclusion Criteria:

          -  ASA/NSAID allergy

          -  Renal disease

          -  Lithium therapy

          -  Complicated cardiovascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Jakobsson, MD, PhD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foot &amp; Ancle Surgical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foot &amp; Ancle Surgical Center</name>
      <address>
        <city>Stockholm</city>
        <zip>11542</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <results_first_submitted>December 7, 2009</results_first_submitted>
  <results_first_submitted_qc>December 9, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2010</results_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jan Jakobsson</name_title>
    <organization>Foot &amp; Ancle Surgical Center</organization>
  </responsible_party>
  <keyword>Day surgery</keyword>
  <keyword>Hallux Valgus</keyword>
  <keyword>Pain</keyword>
  <keyword>Analgesics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hallux Valgus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patient recruited and analysed between october 2008 and june 2009</recruitment_details>
      <pre_assignment_details>Two patients were excluded after randomization forgot study medication and questionnaire leaving the hospital</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etoricoxib</title>
          <description>Active study drug:
Etoricoxib 90 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Control Tramadol</title>
          <description>Tramadol 100 mg slow release twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50">November 2008</participants>
                <participants group_id="P2" count="50">November 2008</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49">All but one randomsied patient</participants>
                <participants group_id="P2" count="49">All but one randomised patient</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoricoxib</title>
          <description>Active study drug:
Etoricoxib 90 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Control Tramadol</title>
          <description>Tramadol 100 mg slow release twice daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Requiring Rescue Medication</title>
        <description>Number of patients requiring any further pain medication</description>
        <time_frame>7 day study period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Rescue Medication</title>
          <description>Number of patients requiring any further pain medication</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain</title>
        <description>VAS score 1-10 1=no pain 10 = worst possible pain, summary variable day 1-7; 7 - 70</description>
        <time_frame>The first 7 days after surgery, during study pain medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Pain Scores, Day 1-7 of Visual Analogue Scale Grading of Pain</title>
          <description>VAS score 1-10 1=no pain 10 = worst possible pain, summary variable day 1-7; 7 - 70</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="8"/>
                    <measurement group_id="O2" value="17" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance to Base Medication</title>
        <description>Number of patients that did not discontinue study medication before day 7</description>
        <time_frame>7-day study period, during study medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance to Base Medication</title>
          <description>Number of patients that did not discontinue study medication before day 7</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gastro-intestinal Symptoms</title>
        <description>Number of patients reporting any gastro-intestinal side effects; nausea and or vomiting, gastritis etc. assessed by patient and documented in written questionnaire</description>
        <time_frame>during the 7- day pain medication period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Gastro-intestinal Symptoms</title>
          <description>Number of patients reporting any gastro-intestinal side effects; nausea and or vomiting, gastritis etc. assessed by patient and documented in written questionnaire</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dizziness/Sleepiness</title>
        <description>Number of patients that experienced dizziness/sleepiness/fatigue, assessed by patient and documented in written questionnaire</description>
        <time_frame>During the 7-day pain medication period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Dizziness/Sleepiness</title>
          <description>Number of patients that experienced dizziness/sleepiness/fatigue, assessed by patient and documented in written questionnaire</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wound Healing</title>
        <description>healing process assessed by a blinded physician during the final outpatient clinic visit assessment graded; Good/neutral/bad</description>
        <time_frame>16 week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Healing</title>
          <description>healing process assessed by a blinded physician during the final outpatient clinic visit assessment graded; Good/neutral/bad</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Goood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Pain Medication</title>
        <description>satisfied or unsatisfied with study medication, assessed by patient in questionnaire</description>
        <time_frame>during the first 20 days after surgery, 1st outpatient clinic visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Pain Medication</title>
          <description>satisfied or unsatisfied with study medication, assessed by patient in questionnaire</description>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessed Overall Satisfaction With Surgery/Outcome</title>
        <description>overall satisfaction with outcome, patients assessed satisfaction with the surgical procedure; satisfied, neutral or unsatisfied, written questionnaire.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessed Overall Satisfaction With Surgery/Outcome</title>
          <description>overall satisfaction with outcome, patients assessed satisfaction with the surgical procedure; satisfied, neutral or unsatisfied, written questionnaire.</description>
          <units>Patients.</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unsatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessed Quality of Life</title>
        <description>Quality of Life evaluated by grading on a Visual Analogue Scale in the written questionnaireisual analogue scale grading 0-100; 0 death and 100 perfect quality of life</description>
        <time_frame>At 16-week post surgery follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>Active study drug:
Etoricoxib 90 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Control Tramadol</title>
            <description>Tramadol 100 mg slow release twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessed Quality of Life</title>
          <description>Quality of Life evaluated by grading on a Visual Analogue Scale in the written questionnaireisual analogue scale grading 0-100; 0 death and 100 perfect quality of life</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="9.4"/>
                    <measurement group_id="O2" value="94.7" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etoricoxib</title>
          <description>Active study drug:
Etoricoxib 90 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Control Tramadol</title>
          <description>Tramadol 100 mg slow release twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jan Jakobsson PI, MD, PhD, Professor</name_or_title>
      <organization>Foot &amp; Ankle Surgical Centre</organization>
      <phone>46702500960</phone>
      <email>jan.jakobsson@ki.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

